Table 2 A comparison of the biochemical profiles between the study group and the reference group.

From: Thioredoxin and tetraspanin 30 (CD63) as potential biomarkers for angioinvasion in papillary thyroid cancer

Parameter

Study group

Median (minimum-maximum)

Reference group

Median (minimum-maximum)

P-value*

TSH

(µIU/ml)

0.76

(0.05–3.83)

1.38

(0.09–3.71)

0.092

FT3

(pg/ml)

2.64

(1.36–3.76)

2.41

(1.0-6.27)

0.883

FT4

(ng/mL)

1.22

(0.54–2.14)

1.83

(0.42–1.82)

0.941

TGB

(ng/ml)

6.41

(0.04–37.05)

0.39

(0.04–3.20)

0.041

TGBAb

(IU/mL)

11.22

(0.6-132.4)

5.99

(0.00-45.10)

0.048

CHOL

(mg/dl)

211.00

(160.00-361.00)

184.70

(99.00-262.00)

0.027

LDL

(mg/dl)

155.50

(92.00-298.00)

109.10

(60.00-175.00)

< 0.001

TG

(mg/dl)

134.00

(70.00-219.00)

128.50

(84.00-151.00)

0.921

HDL

(mg/dl)

39.10

(29.00–56.00)

45.80

(40.00–77.00)

0.043

25-OH vit. D

(ng/ml)

28.21

(10.5–51.2)

27.18

(12.2–62.6)

0.567

GLUCOSE

(mg/dL)

96.05

(77–114)

96.44

(69–118)

0.518

CRP

(mg/L)

2.15

(0.4–5.8)

3.4

(0.2–8.6)

0.557

  1. Values marked in bold and underlined indicate statistically significant results at the level of p < 0.05.
  2. *U-Mann Whitney test.
  3. CHOL, cholesterol; CRP, C reactive protein; PTC, papillary thyroid cancer; fT3, free triiodothyronine; fT4, free thyroxine; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglyceride; TGB, thyroglobulin; TGBAb, antithyroglobulin antibodies; TSH, thyroid-stimulating hormone; vit. D, vitamin D.
Back to article page